University of California

The United States Government As Represented by the Department of Veterans Affairs

Sloan-kettering Institute for Cancer Research

Cheryl I Champion

James N Miller

David R Blanco

Michael A Lovett

Leonard H Rome

Valerie A Kickhoefer

Kathleen A Kelly

David A Haake

Paul J Tempst

Jian Yang

Steven M Dubinett

Sherven Sharma

Upendra K Kar

Linda M Liau

Ellen S Shang

Jonathan T Skare

Tajib A Mirzabekov

Bruce L Kagan

Denise M Foley

Janina Jiang

Isaac Yang

The invention relates to compositions of vault complexes for use as adjuvants for stimulating a cellular immune response to an antigen, for example a tumor antigen, and methods of using the vault complexes in the treatment of diseases, such as cancer.

Vault immunotherapy

Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.

Vault compositions for immunization

Methods and compositions are provided herein for immunizing a subject against Chlamydial genital infection by administering to the subject an effective amount of a Chlamydial immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. In some aspects, the vault-like-particles are administered to the nasal mucosa. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity at mucosal surfaces while reducing inflammation associated withinfection.

Vault compositions for immunization against Chlamydia genital infection

Vault compositions for immunization against chlamydia genital infection

An antigenic preparation is provided which contains a 31 Kd outer membrane protein from Leptospira which can be used immunologically as a vaccine for leptospirosis caused by this organism.

Cloned Leptospira outer membrane protein

Antigenic rare outer membrane proteins of Spirochaetaceae are obtained from organisms extracted from infected tissue by a novel process of isolation utilizing a discontinuous Ficoll gradient separation, release of outer membrane in a low isotonic and low pH buffer and identification of outer membrane by use of a lipid soluble dye. Four antigenic rare outer membrane proteins of subsp. useful in diagnosis and prophylaxis of syphilis are provided. Also provided is the amino acid sequence of a rare outer membrane protein of subsp. and the nucleotide sequence encoding it.

Methods for isolating T. pallidum rare outer membrane proteins

The present invention presents three B. burgdorferi membrane proteins: Oms28, Oms45, and Oms66, each of about 28, 45, and 66 kDa respectively; and with average single channel conductances of about 0.6, 0.22, and 9.7 nS, respectively. Also disclosed are the methods for purifying these proteins from B. burgdorferi, methods for producing antibodies to these proteins, and the resulting antibodies. These proteins and their immunogenic fragments, and antibodies capable of binding to them are useful for inducing an immune response to pathogenic B. burgdorferi as well as providing a diagnostic target for Lyme disease. Further disclosed are the nucleotide and amino acid sequences, the cloning of the genes encoding the proteins and their recombinant proteins, and methods for obtaining the foregoing. Other B. burgdorferi outer membrane spanning proteins (Oms) obtainable by the isolation and purification methods of the present invention.

Borrelia burgdorferi outer membrane proteins

The present invention provides EppA polypeptide, a Borrelia burgdorferi virulence protein. This 17-kD outer membrane protein has been designated EppA for exported plasmid protein A.

Cloned borrelia burgdorferi virulence protein

Antigenic rare outer membrane proteins of Spirochaetaceae are obtained from organisms extracted from infected tissue by a novel process of isolation utilizing a discontinuous Ficoll gradient separation, release of outer membrane in a low isotonic and low pH buffer and identification of outer membrane by use of a lipid soluble dye. Four antigenic rare outer membrane proteins of T. pallidum subsp. pallidum useful in diagnosis and prophylaxis of syphilis are provided. Also provided is the amino acid sequence of a rare outer membrane protein of T. pailidum subsp. pallidum and the nucleotide sequence encoding it.

Nucleotide sequences of a T. pallidum rare outer membrane protein

Antigenic rare outer membrane proteins of Spirochaetaceae are obtained from organisms extracted from infected tissue by a novel process of isolation utilizing a discontinuous Ficoll gradient separation, release of outer membrane in a low isotonic and low pH buffer and identification of outer membrane by use of a lipid soluble dye. Four antigenic rare outer membrane proteins of T. pallidum subsp. pallidum useful in diagnosis and prophylaxis of syphilis are provided. Also provided are the amino acid sequences of two rare outer membrane proteins of T. pallidum subsp. pallidum, called TROMP 1 and TROMP 2, and the nucleotide sequences encoding them.

Nucleotide sequences of T. pallidum rare outer membrane protein

Cloned leptospira outer membrane protein

A polynucleotide encoding a 17-kD virulence protein, called EppA, from Borrelia burgdorferi is provided. The protein encoded by the polynucleotide of the invention is useful immunologically as a vaccine for Lyme borreliosis caused by B. burgdorferi. Methods and kits for detection of EppA polynucleotide are also provided.

Growing community of inventors

Los Angeles, CA, United States of America

Cheryl I Champion